Objective-To evaluate the benefit to risk ratio of thrombolytic treatment in patients with small inferior acute myocardial infarction (AMI). Controlled studies relating the benefit from thrombolysis with initial electrocardiographic features are scarce and of limited sample size. Thrombolysis is claimed to be the treatment of choice for patients with acute myocardial infarction (AMI) of less than 12 hours duration presenting with ST segment elevation on their admission electrocardiogram (ECG), irrespective of the site of infarction.' 2 Mortality benefit in patients with inferior AMI is less, however, than in those with anterior AMI, and there is conflicting evidence regarding the efficacy of reperfusion treatment in patients with small inferior AMI.3 6 Inclusion of these low risk patients in thrombolytic trials may be a major reason why the benefit of thrombolytic treatment in patients with inferior AMI has been less dramatic than in those with anterior AMI.5
Design-Retrospective study of 728 patients with a first inferior AMI of six hours' duration from the Intravenous Streptokinase in Acute Myocardial Infarction (ISAM) study comparing streptokinase with placebo stratified by the initial sum ST segment elevation (EST) of 0O8 mV or less and greater than 0O8 mV, and 636 patients from the International Joint Efficacy Comparison of Thrombolytics (INJECT) trial comparing double blind streptokinase with reteplase stratified by either EST or the presence of precordial ST segment depression. Results-ISAM study patients with an EST of greater than 0-8 mV had a significant mortality benefit from streptokinase throughout six years, while those with an EST of 0O8 mV or less showed a trend to higher mortality at six months (6.3% streptokinase v 5 1% placebo). Despite significantly smaller infarcts and fewer clinical complications in patients with an EST of 0O8 mV or less (ISAM and INJECT) or the absence of precordial ST segment depression (INJECT) thrombolytic treatment was associated with higher early mortality than in those with initially larger ST segment deviations. Conclusion-Thrombolytic treatment in patients with inferior AMI presenting with larger ST segment deviations is associated with improved survival throughout six years. The risk to benefit ratio, however, in terms of early mortality in patients who have an EST of 0O8 mV or less and no precordial ST segment depression may be unfavourable.
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Keywords: inferior myocardial infarction; ST segment deviation; thrombolytic treatment; mortality Thrombolysis is claimed to be the treatment of choice for patients with acute myocardial infarction (AMI) of less than 12 hours duration presenting with ST segment elevation on their admission electrocardiogram (ECG), irrespective of the site of infarction.' 2 Mortality benefit in patients with inferior AMI is less, however, than in those with anterior AMI, and there is conflicting evidence regarding the efficacy of reperfusion treatment in patients with small inferior AMI. 3 6 Inclusion of these low risk patients in thrombolytic trials may be a major reason why the benefit of thrombolytic treatment in patients with inferior AMI has been less dramatic than in those with anterior AMI. 5 Placebo controlled studies to clarify the precise indication for thrombolytic treatment in patients with inferior AMI are now unethical, and former controlled studies are scarce and limited by the small sample sizes.78 In the present study data from the Intravenous Streptokinase in Acute Myocardial Infarction (ISAM) study9 dataset, which provides a large well characterised cohort of patients, in whom initial ST segment elevation was measured, were reanalysed. Precordial ST segment depression was not measured in the ISAM study. Therefore, to bring the placebo controlled results on the initial sum hours of the onset of symptoms in whom ST segment elevations of at least 0-1 mV in two limb leads or 0-2 mV in two contiguous chest leads were present were eligible. segment as the baseline. As in other studies78 EST was calculated from leads II, III, aVF, V5, and V6. In the INJECT trial substudy, EST segment depression in leads V1-V4 was also measured. In accordance with other authors,5 significant precordial ST segment depression was defined as 0 1 mV or more in at least two of leads V1-V4.
ENZYME ANALYSIS
In the ISAM study, serum activity of creatine kinase (CK) isoenzyme, MB fraction, was measured at two hour intervals. The enzyme infarct size was calculated from the area under the curve. In the INJECT trial, peak serum activity of creatine kinase isoenzyme was measured in the participating hospitals and is expressed as a fraction of the upper normal limit of the different methods used.
QUANTITATIVE ANGIOGRAPHIC ANALYSIS
In the ISAM study, cardiac catheterisation and angiography were performed one month after infarction. The ejection fraction was calculated from an angiogram in a 30°right anterior oblique projection according to the area length method. Regional wall motion abnormalities were analysed in angiograms performed in the 300 right anterior oblique and 60°left anterior oblique projection, and calculated in square units as "regional dyssynergic area" (DA). Briefly, the end diastolic and end systolic silhouettes were superimposed and divided into 48 segmental radii. The area between radii shortening by less than two standard deviations (SD) and the 2 SD range for systolic shortening in healthy individuals were considered as the DA. A moving average technique that is fairly common in time series analysis was used to detect deviations from the linear Cox model. First, discrete six month mortalities were calculated for intervals in steps of 0 1 mV. Second, weighted averages of the discrete mortalities were applied using a triangular weight function averaging over nine adjacent classes to achieve local smoothing of the crude mortality values. Ascending or descending trends in mortality were expressed by non-parametric rank biserial correlations rbi, according to Glass ," which can be tested with the Mann-Whitney U statistical test. The correlation coefficient and the corresponding P value can be interpreted in the same way as the Pearson correlation coefficient with P value for continuous variables.
Results

CUT OFF POINT FOR LACK OF MORTALITY BENEFIT
Figure IA (Cox regression analysis) and 1B (weighted averages) show six month mortality with the two applied estimation methods plotted by steps of increasing levels of EST on the baseline ECG for the ISAM patients (376 allocated to streptokinase and 352 to placebo) and INJECT trial patients with a first inferior AMI. In both models, patients in the ISAM study given placebo showed a continuous increase in mortality. In contrast, the curves for streptokinase treated patients were flat with some trend to lower mortality at higher EST. The interaction term of the Cox model was significant (2P = 0025, fig 1A) as was the rank correlation rbis = 0-23 (P = 0029 one sided, fig   1B) for the ISAM study placebo group, while the rank correlation in the ISAM streptokinase group was not significant (rbis = -0-02). In the INJECT trial, the mortality curves for patients randomised to thrombolytic treatment with either streptokinase or reteplase were also flat like those for the ISAM study streptokinase group (figs 1A and 1B). group.bmj.com on July 7, 2017 -Published by http://heart.bmj.com/ Downloaded from Basically, each approach gives the same impression. As the functional form of the global estimate is defined by the model rather than the data, however, Cox analysis seems to be less useful to define a cut off point. Therefore, the local smoothing method by moving average technique was used ( fig 1B) . According to this model mortality functions cross between 0-8 mV and 0 9 mV. Thus, lack of mortality benefit from thrombolytic treatment was assumed for patients with a smaller EST on their baseline ECG defined by the cut off point of EST of 0-8 mV or less.
INFARCT SIZE AND LEFT VENTRICULAR FUNCTION
Patients with an EST of 0-8 mV or less in the ISAM study had relatively low enzyme release and a relatively normal ejection fraction. Benefit from thrombolytic treatment was small and statistically non-significant. Patients figure 2A show a sustained mortality benefit throughout six years (P = 006). The cut off point of 0-8 mV was derived from figure 1B. A shift to the right to 1 0 mV was associated with mortality differences in favour of streptokinase, which were conventionally significant.
In contrast, an initial EST of 0-8 mV or less in patients allocated to streptokinase was associated with a trend to higher six month mortality (6-3 v 5*1% placebo) and no long term mortality differences between patients given streptokinase or matching placebo ( fig 2B) . Table 3 shows that the ischaemic area at risk as measured from the extent of EST was significantly smaller and the peak creatine kinase (CK) activity significantly lower in patients with either an EST of 0-8 mV and less or absence of precordial ST segment depression than in those with larger ST segment deviation. In contrast, mortality at six months tended to be higher in patients with lesser ST segment deviation. The data are similar when analysed separately for patients randomised to reteplase or streptokinase. Table 4 shows mortality and peak CK levels for patients with smaller or larger EST values combined with the presence or absence of precordial ST segment depression. The peak CK activity was smallest in patients with a smaller EST and absence of significant precordial ST segment depression, highest in patients with larger EST combined with precordial ST segment depression, and intermediate with either smaller EST and presence or larger EST and absence of precordial ST segment depression (P < o OOO1).
Paradoxically, as in ISAM study patients with smaller EST allocated to streptokinase, mortality tended to be higher in the group with a smaller EST and absence of precordial ST segment depression than in the other three groups with larger ST segment deviations in different combinations (mean mortality at six months 6-9 v 5 2% and mean peak CK 6&8 v 11-8, P < 0-0001). Causes of death within the first 35 days in patients with a small EST and absence of precordial ST segment depression were recurrent myocardial infarction or ven- (table 1) . Currently, the presence or absence of precordial ST segment depression is preferred for prediction of infarct size in inferior AMI.68 Precordial ST segment depression reflects a larger area of ischaemia with extension to posterolateral or inferoseptal regions, indicative of larger enzymatic infarct size and worse regional and global left ventricular function. '7-19 Studies before the thrombolytic era showed that these patients had higher short and long term mortality.5 18 Bates et al I also reported higher complication rates and worse left ventricular function after reperfusion treat-ment. These findings are confirmed by the present study, which, in addition, shows that the data are closely similar in patients stratified by an EST of greater than 0-8 mV (tables 2 and 3). This suggests that large inferior ST segment elevation often coincides with precordial ST segment depression, and that for simplicity the presence of precordial ST segment depression may be sufficient to identify patients with potentially larger infarcts. Several factors, however, alter the magnitude and direction of the ST segment vector in AMI. 17 (table 1) . This result corroborates previous studies in which significant benefit from thrombolysis in patients with either a larger EST or the presence of significant precordial ST segment depression was described.78 In keeping with the present analysis in patients with lesser amounts of ST segment deviation, left ventricular function in the control groups was relatively well preserved and improvement by thrombolytic treatment was small.78
These data are valid for patient groups of sufficient sample size. In individual patients, however, the prognostic merit of the extent of initial ST segment deviation is more limited. The overall correlations with enzymatic infarct size or final left ventricular function are fairly low.8 15 16 In fact, one of three patients with inferior AMI, who had initially smaller ST segment elevations, developed a larger infarct. '6 Nevertheless, thrombolytic treatment in this generally low risk population would not be justified if an adverse effect on early mortality is suspected.
EVIDENCE OF INCREASED MORTALITY RISK WITH THROMBOLYTIC TREATMENT?
In the INJECT trial derived analysis mortality closely parallels that of the streptokinase treated patients in the ISAM study (figs 1A and 1B). Streptokinase clearly improved short and long term survival in patients who had an £ST of more than 0O8 mV compared with that in those who received placebo in the ISAM study (figs 1 and 2). The magnitude of mortality benefit approaches that in patients with anterior AMI.
In patients with a smaller £ST, however, the death rates at six months tended to be higher in those allocated to streptokinase than in those allocated to placebo. In the INJECT trial all patients had thrombolytic treatment. Patients with lesser initial ST segment changes had significantly smaller infarcts and fewer clinical complications than those with an EST of greater than 0-8 mV or the presence of precordial ST segment depression (tables 2 and 3). In contrast, as in the streptokinase group of the ISAM study (fig 1) , early mortality was higher in patients who had lesser ST segment deviations (tables 3 and 4) . The virtually identical findings with thrombolytic treatment in both trials not only support the assumption of no benefit but even provide suggestive evidence for a slight increase in early mortality risk in patients with potentially small inferior AMI. As the sample size is far too small, an increased mortality risk cannot be substantiated by our data. It becomes apparent, however, if we assume that a small improvement in left ventricular performance within the near normal range (table 1) is not associated with any mortality benefit. Then the risks inherent to thrombolytic treatment will not be counterbalanced. Thrombolysis carries the risk of lethal bleeding complications and is associated with an early mortality hazard supposedly caused by reperfusion injury.' The Fibrinolytic Therapy Trialists' Collaborative Group' overview showed a non-significant overall mortality benefit from thrombolytic treatment of only 09% (absolute 7-5 v 8-4% control) for patients with inferior ST segment elevation, and there was an excess of deaths soon after thrombolysis (2-6% v 1-9% allocated control).' As an excess of early deaths was not observed in patients with anterior ST segment elevation and the mortality benefit of streptokinase in patients presenting with larger inferior ST segment elevation was comparable to that known for anterior AMI patients (fig 1) , the excess of early deaths of patients with inferior AMI are probably mainly caused by those presenting with small ST segment deviations, which are not outweighed by later mortality benefit.
LIMITATIONS
In the initial ISAM study analysis the amount of ST segment elevation on the admission ECG was not a prognostic indicator for an early mortality risk in patients with inferior AMI allocated streptokinase (in contrast to placebo). This might have reflected a game of chance. Confirmation by the INJECT trial ECG substudy, however, makes a play of chance unlikely. The present evaluation is clearly a retrospective subgroup analysis with its limitations. Such analyses are usually appropriate to generate a hypothesis for testing in a prospective randomised controlled trial. It is unlikely, however, that such an effort will be undertaken in the future because of the huge sample size required to prove a small mortality difference in patients, who generally have a relatively low risk of dying. Thus, the suspicion of a small increase in early mortality caused by thrombolytic treatment in patients with a small inferior AMI will probably not be substantiated on the basis of a controlled trial.
How should the emerging concern about a possibly harmful effect of an accepted treatment in patients with AMI be managed? Such potentially important clinical data should not be ignored but rather presented to the medical community. Physicians may then decide how to consider these effects when making clinical decisions concerning patients with AMI.
Conclusions
Thrombolytic treatment is clearly indicated in patients with inferior AMI presenting within six hours from the onset of symptoms with either large infero(lateral) ST segment elevation or concomitant precordial ST segment depression. In addition, thrombolysis is beneficial in patients with an ST segment elevation of 0<1 mV or more in lead V4R, indicating right ventricular involvement. 21 In contrast, the benefit from such treatment in patients with an initial EST of 0-8 mV or less combined with a precordial EST segment depression of less than 0-2 mV is at least small. Thrombolysis may even carry an unfavourable benefit to risk ratio, particularly in patients at high risk for intracranial haemorrhage such as the elderly and those with hypertension or previous cerebrovascular events.2223 Thrombolytic treatment should be considered only if small ST segment deviations are associated with advanced heart block or haemodynamic instability indicating larger infarcts.6 As with all treatments, patient selection has to be guided by weighing the potential benefit against the potential risks. In the INJECT trial ECG substudy, 28% of patients with inferior AMI had small ST segment deviations (table 4). For inclusion into the INJECT trial ST segment elevation of 0 1 mV or greater in at least two limb leads was required. As it is common clinical practice to treat those with even lower ST segment elevations with thrombolytics, the proportion of patients in whom thrombolysis should be avoided is probably even larger. Whether such patients may benefit from direct coronary angioplasty is not known and remains speculative. The prognosis for patients with a first small inferior AMI is usually good and so any aggressive therapeutic approach may cause more harm than benefit. 
